KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.

The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guideline for evaluation, classification, and stratification of chronic kidney disease (CKD) was published in 2002. The KDOQI guideline was well accepted by the medical and public health communities, but concerns and criticisms arose as new evidence became available since the publication of the original guidelines. KDIGO (Kidney Disease: Improving Global Outcomes) recently published an updated guideline to clarify the definition and classification of CKD and to update recommendations for the evaluation and management of individuals with CKD based on new evidence published since 2002. The primary recommendations were to retain the current definition of CKD based on decreased glomerular filtration rate or markers of kidney damage for 3 months or more and to include the cause of kidney disease and level of albuminuria, as well as level of glomerular filtration rate, for CKD classification. NKF-KDOQI convened a work group to write a commentary on the KDIGO guideline in order to assist US practitioners in interpreting the KDIGO guideline and determining its applicability within their own practices. Overall, the commentary work group agreed with most of the recommendations contained in the KDIGO guidelines, particularly the recommendations regarding the definition and classification of CKD. However, there were some concerns about incorporating the cause of disease into CKD classification, in addition to certain recommendations for evaluation and management.

[1]  S. Yusuf,et al.  Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. , 2011, Kidney international.

[2]  A. Levey A decade after the KDOQI CKD guidelines. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  J. Coresh,et al.  Short-term change in kidney function and risk of end-stage renal disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  J. Cohn,et al.  Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure , 2009, Circulation.

[5]  K. Heathcote,et al.  Prevalence and duration of exercise induced albuminuria in healthy people. , 2009, Clinical and investigative medicine. Medecine clinique et experimentale.

[6]  J. Kaufman,et al.  Age affects outcomes in chronic kidney disease. , 2007, Journal of the American Society of Nephrology.

[7]  Norbert Lameire,et al.  Notice , 2012, Kidney International Supplements.

[8]  C. Price,et al.  Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  David C. Wheeler,et al.  Notice , 2012, Kidney International Supplements.

[10]  F. Dumler,et al.  Prospective nutritional surveillance using bioelectrical impedance in chronic kidney disease patients. , 2005, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[11]  Finlay MacKenzie,et al.  How should proteinuria be detected and measured? , 2009, Annals of clinical biochemistry.

[12]  H E de Wardener,et al.  Effect of urinary extracts from salt-loaded man on urinary sodium excretion by the rat. , 1972, Kidney international.

[13]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[14]  S. Balamuthusamy,et al.  Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. , 2008, American heart journal.

[15]  W. G. Walker,et al.  Plasma aldosterone regulation in anephric man. , 1973, Kidney international.

[16]  C. Fraser,et al.  Selecting the optimum specimen for assessing slight albuminuria, and a strategy for clinical investigation: novel uses of data on biological variation. , 1987, Clinical chemistry.

[17]  Patrick D. Brophy,et al.  KDOQI US commentary on the 2012 KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for acute kidney injury , 2013 .

[18]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[19]  B. Kasiske,et al.  Evidence and outcomes in CKD. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  J. Lieske,et al.  A reference system for urinary albumin: current status , 2013, Clinical chemistry and laboratory medicine.

[21]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[22]  Bertram L Kasiske,et al.  The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. , 2011, Kidney international.

[23]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[24]  M. Al-mallah,et al.  Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. , 2008, Journal of cardiac failure.

[25]  K. Lipska,et al.  Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency , 2011, Diabetes Care.

[26]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[27]  O. Djurdjev,et al.  Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  K. Kalantar-Zadeh,et al.  Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[29]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[30]  D. Meier,et al.  Five policies to promote palliative care for patients with ESRD. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[31]  Amy C. Dwyer,et al.  Special Feature Critical and Honest Conversations: the Evidence behind the " Choosing Wisely " Campaign Recommendations by the American Society of Nephrology , 2012 .

[32]  Jennifer MacRae,et al.  Overview of the Alberta Kidney Disease Network , 2009, BMC nephrology.

[33]  A. Khwaja KDIGO Clinical Practice Guidelines for Acute Kidney Injury , 2012, Nephron Clinical Practice.

[34]  J. Adamson,et al.  Notice , 2012, Kidney International Supplements.

[35]  A. Zanchetti,et al.  Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. , 2010, Journal of the American College of Cardiology.

[36]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[37]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[38]  Supplemental Tables,et al.  KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). , 2009, Kidney international. Supplement.

[39]  A. Morsing,et al.  GFR prediction from cystatin C and creatinine in children: effect of including body cell mass. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  R. Califf,et al.  The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2008, American heart journal.

[41]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[42]  Josef Coresh,et al.  Cystatin C versus creatinine in determining risk based on kidney function. , 2013, The New England journal of medicine.

[43]  Benjamin J. Epstein,et al.  Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure , 2007 .

[44]  Y. Chan,et al.  Natriuretic peptides in chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[45]  A. Levey,et al.  Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group. , 1991, Journal of the American Society of Nephrology : JASN.

[46]  Mark Woodward,et al.  Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. , 2011, Kidney international.

[47]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[48]  S. Sethi,et al.  Estimating kidney function in a multiethnic Asian population with multiple filtration markers. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[49]  T. Connor,et al.  Renal handling of calcium and phosphate during mineralocorticoid "escape" in man. , 1972, Kidney international.

[50]  R. Bilous,et al.  KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  Kdoqi Disclaimer K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[52]  C. Price,et al.  Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. , 2005, Clinical chemistry.

[53]  C. Anderson,et al.  Adherence to a healthy lifestyle and all-cause mortality in CKD. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[54]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[55]  A. Go,et al.  FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.

[56]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[57]  Hans L. Hillege,et al.  Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure , 2006, Circulation.

[58]  Laura E. Clark,et al.  Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. , 2011, Kidney international.

[59]  Bruce Kupelnick,et al.  K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease , 2004 .

[60]  A. Moss Revised dialysis clinical practice guideline promotes more informed decision-making. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[61]  H. Wiemann,et al.  Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. , 2001, European journal of heart failure.

[62]  J. Adamson,et al.  KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease , 2012 .

[63]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[64]  Sylvia Stracke,et al.  CUBN is a gene locus for albuminuria. , 2011, Journal of the American Society of Nephrology : JASN.

[65]  M. Murtaugh,et al.  Associations of body size with metabolic syndrome and mortality in moderate chronic kidney disease. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[66]  C. Whitney,et al.  Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2013, MMWR. Morbidity and mortality weekly report.

[67]  Jackson T. Wright,et al.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.

[68]  M. S. Kirkman,et al.  Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011, Diabetes Care.

[69]  Chris Jones,et al.  Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[70]  R. Foley,et al.  Serum troponin T measurement in patients with chronic renal impairment predicts survival and vascular disease: a 2 year prospective study. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[71]  A. Go,et al.  Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC]). , 2013, The American journal of cardiology.

[72]  Lorien S. Dalrymple,et al.  Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death , 2010, Journal of General Internal Medicine.

[73]  P. Stevens,et al.  Does urinary tract infection cause proteinuria or microalbuminuria? A systematic review. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[74]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.

[75]  S. Schinner,et al.  Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[76]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[77]  J. Griffith,et al.  The Framingham predictive instrument in chronic kidney disease. , 2007, Journal of the American College of Cardiology.

[78]  B. Eriksen,et al.  The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. , 2006, Kidney international.

[79]  E. Ellis,et al.  Proteinuria in children. , 1991, The Journal of the Arkansas Medical Society.

[80]  G. Beck,et al.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. , 1994, The New England journal of medicine.

[81]  Tom Greene,et al.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. , 2002, JAMA.

[82]  J. Coresh,et al.  One-Year Change in Kidney Function Is Associated with an Increased Mortality Risk , 2012, American Journal of Nephrology.

[83]  W. Hermann,et al.  Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure , 2001 .

[84]  Satoko Nakamura,et al.  Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[85]  V. Moyer,et al.  Screening for Chronic Kidney Disease: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[86]  G. Beck,et al.  C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. , 2005, Kidney international.

[87]  A. Macleod,et al.  Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD) , 2009 .

[88]  J. Beizer,et al.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. , 2005, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[89]  E. Schaeffner,et al.  Two Novel Equations to Estimate Kidney Function in Persons Aged 70 Years or Older , 2012, Annals of Internal Medicine.